Find investors
← Back to all investors
ML
ResearchedAngel Investors

Matthew Lee

Vice President

Angel InvestorsSeed Round
Pitch Matthew

Get their honest, personalized take on your startup.

Sign in to pitch Matthew

At a glance

Full Name
Matthew Lee
Title
Partner
Firm
Penfund
Firm Type
Private debt / direct lending investor
Investment Stage
North American middle-market private debt; senior debt, junior capital, unitranche, mezzanine, second lien, private high-yield debt, delayed-draw facilities, and equity co-investments
Check Size
Penfund says it can hold up to C$300 million per transaction, or USD equivalent
Target Company Profile
Middle-market companies, typically with at least $20 million of annual EBITDA, focused strategies, below-average cyclicality, entrenched market positions, stable markets, strong returns on capital, stable free cash flow, and capable management teams
Sector Focus
Healthcare services, distribution, automotive aftermarket, healthcare, consumer, financial services, business services
Geographic Focus
North America
Location
Toronto, Ontario, Canada

Background

Matthew Lee is a Partner at Penfund, a Toronto-based provider of capital to North American middle-market companies. Penfund’s team page says he has more than 10 years of experience across private debt, equity investing, and investment banking, and that he joined Penfund in 2015. Since then, he has completed investments across sectors including distribution, automotive aftermarket, healthcare, and consumer.

Before Penfund, Lee worked in the Investment Banking division of TD Securities, where Penfund says he was involved in financing and M&A transactions across a variety of industries. Third-party career profiles list his TD Securities tenure as beginning in 2012 and his Penfund career as progressing through Associate, Senior Associate, Vice President, Principal, and Partner.

Lee holds a BBA from the Schulich School of Business at York University and is a CFA charterholder. His LinkedIn profile identifies him as a Partner at Penfund and describes him as Penfund’s healthcare services sector lead.

Penfund itself was founded in 1979 and is investing senior and junior capital through Penfund Prime and Penfund Capital Fund VII. The firm says it has deployed more than C$4.3 billion across 75 investments since 2000 and has approximately C$3.5 billion in assets under management.

Investment Thesis & Focus

  • Penfund is not an angel or seed-stage investor based on current verified sources; it is a middle-market private credit/direct lending firm focused on North American borrowers.
  • The firm provides senior debt, second lien debt, private high-yield debt, unitranche debt, secured and unsecured mezzanine debt, delayed-draw facilities, and equity co-investments.
  • Penfund says it is a “relationship-oriented, hold-to-maturity lender” and can hold up to C$300 million per transaction, or USD equivalent.
  • Target borrowers typically generate at least $20 million of annual EBITDA and have focused strategies, below-average cyclicality, entrenched market positions, stable markets, strong free cash flow, and capable management teams.
  • Sector specialization includes consumer, business services, healthcare, financial services, automotive aftermarket, distribution, and consumer staples. Lee’s own profile notes completed investments in distribution, automotive aftermarket, healthcare, and consumer, while LinkedIn identifies him as healthcare services sector lead.
  • On Penfund Prime, Lee stated: “Prime will be a trusted financing partner for our private equity sponsor and borrower relationships through all market conditions.”
  • On Penfund’s 2026 DOCS Dermatology investment, Lee said dermatology has “compelling long-term fundamentals” and described DOCS as a high-quality platform with a thoughtful growth strategy and strong provider-centric culture.

Notable Investments

  • DOCS Dermatology Group - Provider of dermatology services; Penfund completed a US$205 million unitranche loan in March 2026 alongside sponsor SkyKnight Capital.
  • CBI Health Group - Canadian home health and outpatient rehabilitation services provider; Penfund portfolio lists a C$70 million mezzanine debt investment from Fund VII.
  • Gastro Health - Gastrointestinal and digestive health treatment provider; Penfund portfolio lists a US$85 million second lien debt and equity co-investment from Fund VI with OMERS as sponsor.
  • Forefront Dermatology - Dermatology practice management services provider; Penfund portfolio lists a US$48.1 million second lien debt and equity co-investment from Fund V with OMERS as sponsor.
  • Mevotech - Supplier of steering, suspension, and driveline replacement components for the automotive aftermarket; TorQuest acquired Mevotech from funds managed by Penfund in July 2024 after Penfund’s roughly 10-year partnership with the company.
  • Arrowhead Engineered Products - Specialty supplier and distributor of aftermarket replacement parts; Penfund portfolio lists multiple second lien debt and equity co-investment entries across Funds VI and VII.
  • Mariner Wealth Advisors - Registered investment advisor; Penfund portfolio lists a US$112.5 million second lien debt investment from Fund VII with Leonard Green & Partners as sponsor.
  • BroadStreet Partners - Insurance brokerage holding company; Penfund portfolio lists a US$100 million second lien debt and equity co-investment from Fund VI with Ontario Teachers’ Pension Plan as sponsor.

Unlock the full research

Get how to approach them, recent activity, sources, contact links — plus pitch their AI twin for a candid read on your raise.

One-time. Stays unlocked for you.